Adam Auton is the Chief Technology Officer at 23andMe, a leading consumer genetics and research company. Since joining in 2015, he has played a pivotal role in advancing the company's human genetics research. His expertise in computational biology and statistical genetics has been instrumental in driving 23andMe's innovative approaches to genetic data analysis.
Who is the CTO of 23andMe?
Before becoming the Chief Technology Officer at 23andMe, Adam Auton had a distinguished career in academia and research. He served as an assistant professor at Albert Einstein College of Medicine, where his team developed innovative algorithmic approaches to leverage large-scale genomic data for understanding human population genetics.
His expertise in computational biology and statistical genetics has been pivotal in advancing 23andMe's mission to revolutionize genetic research and personalized healthcare.
Work History
Adam Auton's work history includes a series of significant roles in both academia and industry. Here is a detailed list of his previous positions:
- 23andMe - Vice President, Human Genetics (2020 to Present)
- 23andMe - Principal Scientist (2018 to Present)
- 23andMe - Senior Statistical Geneticist (2015 to Present)
- Albert Einstein College of Medicine - Assistant Professor (2012 to 2015)
- University of Oxford - Postdoctoral Researcher (2008 to 2011)
- Cornell University - Postdoctoral Researcher (2007 to 2009)
Education History
Adam Auton's educational journey is marked by a strong foundation in both physics and statistical genetics. He earned his Master of Science (MSc) in Physics from the University of Bristol, where he studied from 1997 to 2001. Following this, he pursued a Doctor of Philosophy (PhD) in Statistical Genetics at the University of Oxford, completing his doctoral studies between 2004 and 2007. This robust academic background laid the groundwork for his subsequent contributions to the fields of computational biology and human genetics.
When did Adam Auton join 23andMe?
Adam Auton joined 23andMe in October 2015 as a Senior Statistical Geneticist. Over the years, he has taken on increasingly significant roles within the company, becoming a Principal Scientist in March 2018 and later advancing to Vice President of Human Genetics in August 2020. As of 2023, Adam Auton has been with 23andMe for approximately eight years. He became the Chief Technology Officer in 2023, further solidifying his pivotal role in the company's ongoing efforts to revolutionize genetic research and personalized healthcare.